Puma Biotechnology, Inc. (NASDAQ:PBYI) CEO Alan H. Auerbach Sells 18,885 Shares of Stock

Puma Biotechnology, Inc. (NASDAQ:PBYI) CEO Alan H. Auerbach sold 18,885 shares of the company’s stock in a transaction dated Tuesday, July 2nd. The shares were sold at an average price of $3.27, for a total transaction of $61,753.95. Following the completion of the transaction, the chief executive officer now directly owns 7,085,435 shares of the company’s stock, valued at $23,169,372.45. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Puma Biotechnology Stock Performance

Shares of Puma Biotechnology stock opened at $3.10 on Wednesday. The firm has a market cap of $149.54 million, a PE ratio of 9.39 and a beta of 1.09. Puma Biotechnology, Inc. has a 1 year low of $2.13 and a 1 year high of $7.73. The firm’s 50-day simple moving average is $3.99 and its 200-day simple moving average is $4.80. The company has a debt-to-equity ratio of 1.07, a quick ratio of 1.38 and a current ratio of 1.46.

Puma Biotechnology (NASDAQ:PBYI) last released its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.12. The firm had revenue of $43.80 million for the quarter, compared to analyst estimates of $41.53 million. Puma Biotechnology had a net margin of 6.79% and a return on equity of 35.49%. Equities analysts forecast that Puma Biotechnology, Inc. will post 0.22 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Puma Biotechnology

Several institutional investors and hedge funds have recently bought and sold shares of PBYI. SG Americas Securities LLC acquired a new stake in Puma Biotechnology during the first quarter worth about $57,000. Ritholtz Wealth Management acquired a new stake in Puma Biotechnology during the fourth quarter worth about $66,000. Crestline Management LP raised its stake in Puma Biotechnology by 6.5% during the fourth quarter. Crestline Management LP now owns 34,774 shares of the biopharmaceutical company’s stock worth $151,000 after acquiring an additional 2,135 shares during the period. Jump Financial LLC raised its stake in Puma Biotechnology by 131.7% during the fourth quarter. Jump Financial LLC now owns 57,200 shares of the biopharmaceutical company’s stock worth $248,000 after acquiring an additional 32,510 shares during the period. Finally, Citigroup Inc. acquired a new stake in Puma Biotechnology during the third quarter worth about $262,000. Institutional investors and hedge funds own 61.29% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently issued reports on PBYI. StockNews.com upgraded shares of Puma Biotechnology from a “hold” rating to a “buy” rating in a research note on Wednesday, June 12th. HC Wainwright restated a “buy” rating and issued a $7.00 target price on shares of Puma Biotechnology in a research note on Monday, June 3rd.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.